Compare Eli Lilly And Co (LLY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Spotify Technology — how do they compare? Eli Lilly And Co trades at $1,175.95 (market cap $1.04T), while Spotify Technology trades at $528.82 (market cap $108.22B). The key difference: Eli Lilly And Co is far larger — about 9.6× Spotify Technology's market cap, and Eli Lilly And Co pays a 0.59% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Spotify Technology for 111 Days on average.
| LLY | SPOT | |
|---|---|---|
Market Cap | $1.04T | $108.22B |
Volume | 3,064,878 | 1,655,796 |
Sector | Health | Media |
52-Week High | $1.28K | $692.04 |
52-Week Low | $799.57 | $412.75 |
Typical Hold Time | 93 Days | 111 Days |
Enterprise Value | $1.09T | $98.23B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Spotify (SPOT) trades at $524.71, up 2.3% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamental improvement with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income of $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst sentiment remains positive with 62% buy ratings and a $606.50 consensus price target.
The outlook remains favorable with continued revenue growth and margin expansion driving upside potential. Key risks include competitive pressures in streaming and market volatility. With strong institutional support and improving cash flow trends, SPOT presents a growth opportunity despite recent technical overbought conditions near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
